Brown Advisory Inc. Raises Stock Holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Brown Advisory Inc. boosted its holdings in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 23.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,338,369 shares of the company's stock after purchasing an additional 438,057 shares during the period. Brown Advisory Inc. owned about 8.35% of Establishment Labs worth $107,729,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital Research Global Investors increased its stake in shares of Establishment Labs by 29.3% during the fourth quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock valued at $88,064,000 after buying an additional 433,484 shares during the period. Voya Investment Management LLC increased its position in Establishment Labs by 7,249.5% during the 4th quarter. Voya Investment Management LLC now owns 408,262 shares of the company's stock valued at $18,809,000 after purchasing an additional 402,707 shares during the period. Assenagon Asset Management S.A. bought a new position in Establishment Labs in the 4th quarter worth $12,898,000. Bamco Inc. NY lifted its position in shares of Establishment Labs by 53.8% in the 4th quarter. Bamco Inc. NY now owns 752,886 shares of the company's stock worth $34,685,000 after purchasing an additional 263,500 shares during the period. Finally, William Blair Investment Management LLC boosted its stake in shares of Establishment Labs by 44.1% during the 4th quarter. William Blair Investment Management LLC now owns 812,825 shares of the company's stock valued at $37,447,000 after purchasing an additional 248,888 shares in the last quarter. Institutional investors own 72.91% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on ESTA shares. Stephens restated an "overweight" rating and issued a $52.00 price objective on shares of Establishment Labs in a report on Thursday, March 6th. Needham & Company LLC began coverage on Establishment Labs in a research report on Monday, April 14th. They set a "hold" rating on the stock. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.40.

Establishment Labs Stock Down 2.3 %

Shares of Establishment Labs stock traded down $0.79 during midday trading on Friday, hitting $34.01. The company had a trading volume of 485,256 shares, compared to its average volume of 466,896. The company has a 50 day moving average of $34.83 and a 200 day moving average of $38.52. The stock has a market capitalization of $981.05 million, a P/E ratio of -13.18 and a beta of 0.73. Establishment Labs Holdings Inc. has a 52-week low of $26.56 and a 52-week high of $60.12. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.13. The firm had revenue of $41.38 million during the quarter, compared to analyst estimates of $41.15 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. Establishment Labs's quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.58) EPS. On average, equities analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.